You don’t have permission to access “http://www.ndtv.com/world-news/israel-gaza-ceasefire-live-updates-israel-launches-operation-returning-home-to-free-hostages-held-by-hamas-9443620” on this server.
Reference…
Blog
-
Access Denied
Access Denied
-
Map Reveals How DNA Mutations Drive Resistance
Every organism’s genome contains mutations that often have unknown biological effects. In partnership with Stanford University (USA), researchers at Charité – Universitätsmedizin Berlin have now discovered a way to predict the…
Continue Reading
-
Can a Sweetener Really Regrow Hair? New Research Says Yes – SciTechDaily
- Can a Sweetener Really Regrow Hair? New Research Says Yes SciTechDaily
- A sweet fix for baldness? Stevia compound boosts hair growth ScienceDaily
- Natural sweetener found to turbocharge baldness treatment New Atlas
- Stevia for hair loss? Study finds…
Continue Reading
-
Microdrama Boom Goes Global at Mipcom
AR is presenting an extensive selection of microdramas from China and beyond at the ongoing Mipcom market.
The company operates across the $7 billion Chinese and $4 billion international short-form content sectors, with a library of 1,000…
Continue Reading
-
Canberra welcomes four global conferences
Mount Stromlo; photo by Visit Canberra Canberra has successfully secured four international conferences spanning space science, artificial intelligence, human-computer interaction, and healthcare, this spring.
The influx of…
Continue Reading
-
Transcriptomic profiles of endocrine-resistant breast cancer | BMC Cancer
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Google Scholar
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32: 1216–1235.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159–82.
Google Scholar
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
Google Scholar
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.
Google Scholar
Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35.
Google Scholar
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.
Google Scholar
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.
Google Scholar
Confederation of Regional Cancer Centres in Sweden. National Clinical Cancer Care Guidelines Breast Cancer. 2024. https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/brost/vardprogram/nationellt-vardprogram-brostcancer.pdf (Accessed 24 Oct 2024).
Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300.
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341–1352.
Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174–86.
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23: 382–392.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058–70.
Google Scholar
Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246–56.
Google Scholar
Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted therapies, sequencing strategies, and beyond in metastatic hormone receptor-positive breast cancer: ASCO guideline clinical insights. JCO Oncol Pract 2024; : OP2400547.
AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25:S18–27.
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771–784.
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836–46.
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717.
Miranda F, Prazeres H, Mendes F, Martins D, Schmitt F. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers. Mol Biol Rep. 2022;49:717–33.
Google Scholar
Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–An overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220–34.
Google Scholar
Rasha F, Sharma M, Pruitt K. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532: 111322.
Google Scholar
Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125:3714–28.
Google Scholar
Saatci O, Huynh-Dam K-T, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med. 2021;99:1691–710.
Google Scholar
Haque MM, Desai KV. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front Endocrinol. 2019;10:573.
Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496–513.
Google Scholar
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An abridged explanation and elaboration. J Natl Cancer Inst. 2018;110:803–11.
Google Scholar
Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119:92–101.
Google Scholar
Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645–59.
Google Scholar
Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13.
Google Scholar
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.
Google Scholar
BEA core facility. Bioinformatics and Expression Analysis. http://www.bea.ki.se/ (accessed 5 Mar2023).
Thermo Fisher Scientific Inc. Transcriptome Analysis Console (TAC) v4.0.3 User Guide. Affymetrix Inc., 2022https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/TAC_v4.0.3_User_Guide.pdf (accessed 24 Oct2024).
Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73.
Google Scholar
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.
Google Scholar
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739–1740.
Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25.
Google Scholar
Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27. https://doi.org/10.1093/nar/28.1.27.
Google Scholar
Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672–8. https://doi.org/10.1093/nar/gkad1025.
The Broad Institute. GSEA User Guide. GSEA. 2004–2024. http://www.gsea-msigdb.org/gsea/doc/GSEAUserGuideFrame.html?_Interpreting_GSEA_Results (Accessed 24 Oct 2024).
Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
Google Scholar
Rueda OM, Sammut S-J, Seoane JA, Chin S-F, Caswell-Jin JL, Callari M, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399–404.
Google Scholar
Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
Google Scholar
Bhuva D, Smyth G, Garnham A. msigdb: An ExperimentHub Package for the Molecular Signatures Database (MSigDB). R package version 1.14.0. 2024. https://davislaboratory.github.io/msigdb.
Zhao X, Rødland EA, Tibshirani R, Plevritis S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. 2015;17:29.
Google Scholar
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.
Google Scholar
R Foundation for Statistical Computing, Vienna, Austria. R: A language and environment for statistical computing. https://www.R-project.org/.
Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, et al. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse. Clin Cancer Res. 2017;23:3035–44.
Google Scholar
Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, et al. Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor–positive HER2-positive breast cancer treated with neoadjuvant anti–HER2-based therapy. Clin Cancer Res. 2021;27:3116–25.
Google Scholar
Microsoft Corporation. Microsoft® Excel® for Microsoft 365 MSO. Available from: https://office.microsoft.com/excel.
Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 2021; 39: 2720–2731.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700–1712.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736–1747.
Yu NY, Iftimi A, Yau C, Tobin NP, van ’t Veer L, Hoadley KA et al. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal A or luminal B breast cancer. JAMA Oncol 2019; 5: 1304–1309.
Ignatov A, Eggemann H, Burger E, Ignatov T. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018;144:1347–55.
Google Scholar
Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.
Google Scholar
Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci 2023; 24. https://doi.org/10.3390/ijms24076834.
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905–31.
Google Scholar
Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135–70.
Google Scholar
Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The changing role of ER in endocrine resistance. Breast. 2015;24(Suppl 2):S60–6.
Google Scholar
Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545–62.
Google Scholar
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–40.
Google Scholar
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
Google Scholar
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018;36:1556–63.
Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Google Scholar
Wang X, Sun Z, Zimmermann MT, Bugrim A, Kocher J-P. Predict drug sensitivity of cancer cells with pathway activity inference. BMC Med Genomics. 2019;12:15.
Google Scholar
Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol. 2021;12: 599586.
Harvell DME, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112:475–88.
Google Scholar
Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, et al. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). J Hematol Oncol. 2018;11:124.
Google Scholar
Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R et al. G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. Int J Mol Sci 2020; 21. https://doi.org/10.3390/ijms21082921.
Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M et al. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer. Cells 2020; 9. https://doi.org/10.3390/cells9071643.
Shen W-J, Zhang Y. RPN1 promotes the proliferation and invasion of breast cancer cells by activating the PI3K/AKT/mTOR signaling pathway. Discov Oncol. 2024;15:25.
Google Scholar
Althobiti M, El-Sharawy KA, Joseph C, Aleskandarany M, Toss MS, Green AR, et al. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Res Treat. 2021;189:621–30.
Google Scholar
Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I et al. Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers 2020; 12. https://doi.org/10.3390/cancers12123557.
Takeshita T, Tokumaru Y, Oshi M, Wu R, Patel A, Tian W, et al. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. Front Oncol. 2022;12: 865024.
Google Scholar
Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19:2057–70.
Google Scholar
Schroth W, Mürdter TE, Schwab M. Unraveling the impact of drug metabolism on tamoxifen response in breast cancer. Cancer Epidemiol Biomarkers Prev. 2025;34(2):221–3.
Google Scholar
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162–80.
Google Scholar
Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA. Cytoscape and EnrichmentMap Nat Protoc. 2019;14(2):482–517.
Google Scholar
Bull C, Byrne RM, Fisher NC, Corry SM, Amirkhah R, Edwards J, et al. Dual gene set enrichment analysis (dualGSEA); an R function that enables more robust biological discovery and pre-clinical model alignment from transcriptomics data. Sci Rep 2024 4;14(1):30202.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14(1):4221.
Google Scholar
Wimmer I, Tröscher AR, Brunner F, Rubino SJ, Bien CG, Weiner HL, et al. Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. Sci Rep. 2018;8:6351.
Google Scholar
Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373-386.e10.
Google Scholar
Continue Reading
-
Phase shift in optical cavities could detect low-frequency gravitational waves – Physics World
Phase shift in optical cavities could detect low-frequency gravitational waves – Physics World